Deciphering the structure and dynamics of quadruplex DNA and DNA-ligand complexes

破译四链体 DNA 和 DNA-配体复合物的结构和动力学

基本信息

  • 批准号:
    9304843
  • 负责人:
  • 金额:
    $ 41.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-06-01 至 2020-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The proposed research will improve the selectivity and efficacy of anticancer therapies by contributing new knowledge about non-canonical G-quadruplex (GQ) DNA structure, and the interactions of GQs with small- molecule ligands. Bioinformatics studies have identified 370,000 sequences with G-quadruplex-forming potential in the human genome. There is now convincing biological evidence that GQs form in vivo and that these structures regulate a variety of cancer-related biological processes, such as telomere protection, oncogene expression, epigenetic modification, and DNA repair. Thus, GQ DNA has been firmly established as an important therapeutic target for cancer. Small molecules that bind selectively to GQ DNA have been identified, and some have been shown to inhibit tumor cells growth; however, exact mechanisms underlying this inhibition are not known. Such small-molecule ligands may ultimately become lead compounds for the generation of novel selective cancer drugs superior to conventional mutagenetic therapies. Unfortunately, DNA-centered drug discovery programs suffer from limited structural information available for GQs, especially in the presence of ligands. The situation is further complicated by high structural diversity of GQs, their contradictory biological functions, and our limited ability to target a specific GQ folding topology. To address these challenges, we propose to perform comprehensive crystallographic investigations focused on telomeric and oncogene promoter G-quadruplexes, both alone and in complex with a variety of small-molecule ligands. This work will be accompanied by spectroscopic and calorimetric studies of the thermodynamic parameters of ligand binding to GQ DNA (e.g., stoichiometry, affinity, selectivity, driving forces). The static structural view of GQs and GQ-ligand complexes will be complemented by rigorous kinetics studies of ligand-assisted GQ folding and structural rearrangements. Kinetic information can help us identify the timescale of G-quadruplex formation and thus biological processes that can be affected by the presence of these structures. Chemical and structural features of ligands essential for G-quadruplex binding or structural rearrangements will be identified from kinetics and structural studies. Furthermore, we propose chemical modification to the scaffold of N-methylmesoporphyrin IX (NMM), which we showed displays unprecedented selectivity for a parallel GQ fold, yet has modest binding affinity. The modifications should lead to new ligands that retain this selectivity but have improved binding affinity. Ligands that display selective GQ interactions in vitro will be tested in vivo for their biological effects, and genomic targets will be identified. Collectively, the proposed work will enhance our understanding of GQ structural plasticity, supply coordinates for drug discovery platforms, shed light on the origin of ligand selectivity for a specific DNA target, and guide the design of novel highly selective anticancer therapies while providing transformative training to Swarthmore undergraduate students.
项目摘要 这项拟议的研究将通过提供新的治疗方案来提高抗癌疗法的选择性和疗效。 关于非典型G-四链体(GQ)DNA结构的知识,以及GQ与小分子的相互作用, 分子配体。生物信息学研究已经确定了1370,000个具有G-四链体形成的序列, 人类基因组的潜力。现在有令人信服的生物学证据表明,GQ在体内形成, 这些结构调节多种癌症相关的生物过程,例如端粒保护, 癌基因表达、表观遗传修饰和DNA修复。因此,GQ DNA已经牢固地确立为 一个重要的癌症治疗靶点。选择性结合GQ DNA的小分子已经被发现, 已经确定,有些已被证明可以抑制肿瘤细胞的生长;然而, 这种抑制是未知的。这样的小分子配体最终可能成为先导化合物, 产生优于常规诱变疗法的新型选择性癌症药物上级。不幸的是, 以DNA为中心的药物发现计划受到GQ可用结构信息有限的影响,特别是 在配体的存在下。由于GQ的高度结构多样性, 矛盾的生物学功能,以及我们针对特定GQ折叠拓扑结构的有限能力。 为了应对这些挑战,我们建议进行全面的晶体学研究 集中在端粒和癌基因启动子G-四链体,无论是单独的,并在复杂的各种 小分子配体。这项工作将伴随着光谱和热量的研究, 配体与GQ DNA结合的热力学参数(例如,化学计量,亲和力,选择性,驱动 力)。GQ和GQ-配体复合物的静态结构视图将由严格的动力学补充 配体辅助的GQ折叠和结构重排的研究。动力学信息可以帮助我们 G-四链体形成的时间尺度以及因此可能受以下物质的存在影响的生物过程: 这些结构。G-四链体结合或结构所必需的配体的化学和结构特征 将从动力学和结构研究中鉴定重排。此外,我们建议化学 我们对N-甲基中卟啉IX(NMM)支架进行了修饰, 对于平行GQ折叠的选择性,但具有适度的结合亲和力。这些修饰应该会导致新的配体 其保留了这种选择性但具有改进的结合亲和力。显示选择性GQ相互作用的配体, 将在体内测试它们的生物学效应,并鉴定基因组靶点。统称 这些工作将加深我们对GQ结构可塑性的理解,为药物治疗提供坐标, 发现平台,揭示了特定DNA靶点的配体选择性的起源,并指导设计 新型高选择性抗癌疗法,同时为斯沃斯莫尔提供变革性培训, 本科生。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quadruplexes in 'Dicty': crystal structure of a four-quartet G-quadruplex formed by G-rich motif found in the Dictyostelium discoideum genome.
  • DOI:
    10.1093/nar/gky290
  • 发表时间:
    2018-06-01
  • 期刊:
  • 影响因子:
    14.9
  • 作者:
    Guédin A;Lin LY;Armane S;Lacroix L;Mergny JL;Thore S;Yatsunyk LA
  • 通讯作者:
    Yatsunyk LA
Water spines and networks in G-quadruplex structures.
  • DOI:
    10.1093/nar/gkaa1177
  • 发表时间:
    2021-01-11
  • 期刊:
  • 影响因子:
    14.9
  • 作者:
    Li K;Yatsunyk L;Neidle S
  • 通讯作者:
    Neidle S
Interactions Between Spermine-Derivatized Tentacle Porphyrins and The Human Telomeric DNA G-Quadruplex.
  • DOI:
    10.3390/ijms19113686
  • 发表时间:
    2018-11-21
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Sabharwal NC;Chen J;Lee JHJ;Gangemi CMA;D'Urso A;Yatsunyk LA
  • 通讯作者:
    Yatsunyk LA
N-methyl mesoporphyrin IX as a highly selective light-up probe for G-quadruplex DNA.
G-quadruplexes in fibrotic scars may open new therapeutic avenues for wound healing.
  • DOI:
    10.1002/1873-3468.13711
  • 发表时间:
    2020-01
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Johnson FB;Yatsunyk LA
  • 通讯作者:
    Yatsunyk LA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Liliya A Yatsunyk其他文献

Liliya A Yatsunyk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Liliya A Yatsunyk', 18)}}的其他基金

Deciphering the structure and dynamics of non-canonical DNA implicated in cancer
破译与癌症相关的非规范 DNA 的结构和动力学
  • 批准号:
    10046709
  • 财政年份:
    2020
  • 资助金额:
    $ 41.05万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 41.05万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 41.05万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 41.05万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 41.05万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 41.05万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 41.05万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 41.05万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 41.05万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 41.05万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 41.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了